Refractory Hepatic Hydrothorax Is an Independent Predictor of Mortality When Compared to Refractory Ascites

Dig Dis Sci. 2022 Oct;67(10):4929-4938. doi: 10.1007/s10620-022-07522-8. Epub 2022 May 9.

Abstract

Background: Hepatic hydrothorax (HHT) is an uncommon but significant complication of cirrhosis and portal hypertension, associated with a worse prognosis and mortality. Nearly 25% of patients with HHT will have refractory pleural effusion. It is unclear if refractory HHT has a different prognosis compared to refractory ascites.

Aims: We aim to evaluate the prognostic significance of refractory HHT when compared to refractory ascites.

Methods: Forty-seven patients who had refractory HHT in a tertiary care center were identified, and matched, retrospectively, one-to-one by age, gender and MELD-Na with 47 patients with refractory ascites. One-year mortality rate was compared between both groups. Cox proportional hazard regression was used to identify the association between different covariates and primary endpoint.

Results: The 1-year mortality was 51.06% in the HHT group compared to 19.15% in the refractory ascites group. The median survival for patients with refractory hepatic hydrothorax was 4.87 months while the median survival for patients with refractory ascites exceeded 1 year. The presence of HHT was statistically significant in predicting the development of 1-year mortality [Hazard Ratio (HR) 4.45, 95% Confidence Interval (CI) 2.25-8.82; P value < 0.001]. Furthermore, refractory HHT remained associated with one-year mortality after adjusting for all other covariates. In a subgroup of patients with MELD-Na ≤ 20, HHT continued to be a significant predictor of one-year mortality (HR 3.30, 95% CI 1.47-7.40; P value 0.004).

Conclusions: Refractory HHT is a significant independent predictor of mortality and offers additional prognostic value.

Keywords: Ascites; Cirrhosis; Hepatic hydrothorax; Liver transplant; MELD-Na; Mortality.

MeSH terms

  • Ascites / etiology
  • Humans
  • Hydrothorax* / etiology
  • Hypertension, Portal* / complications
  • Liver Cirrhosis / complications
  • Retrospective Studies